Community Financial Services Group LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 3.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,693 shares of the company’s stock after buying an additional 1,212 shares during the quarter. Community Financial Services Group LLC’s holdings in Zoetis were worth $5,490,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cherry Creek Investment Advisors Inc. lifted its stake in Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares in the last quarter. Hancock Whitney Corp raised its position in shares of Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after buying an additional 61 shares in the last quarter. Strategy Asset Managers LLC boosted its stake in Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after buying an additional 62 shares during the period. Procyon Advisors LLC grew its position in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares in the last quarter. Finally, Aberdeen Wealth Management LLC increased its stake in Zoetis by 1.9% in the 3rd quarter. Aberdeen Wealth Management LLC now owns 3,566 shares of the company’s stock worth $697,000 after acquiring an additional 68 shares during the last quarter. 92.80% of the stock is owned by institutional investors.
Zoetis Trading Up 1.5 %
NYSE:ZTS opened at $174.47 on Wednesday. The firm has a market capitalization of $78.72 billion, a P/E ratio of 32.80, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a fifty day moving average of $169.16 and a 200 day moving average of $179.15. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.
Zoetis Dividend Announcement
Insider Buying and Selling
In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on ZTS shares. Morgan Stanley dropped their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler dropped their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday. Finally, Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $214.00.
View Our Latest Research Report on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Recommended Stories
- Five stocks we like better than Zoetis
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- 3 REITs to Buy and Hold for the Long Term
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- The Role Economic Reports Play in a Successful Investment Strategy
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.